Recent Updates
Recently added Catalysts
VCYT Neutral Sentiment Score: 50/100

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Key Takeaway: Veracyte has announced the date for its first quarter 2026 financial results release, which is set for May 5, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will likely be provided at that time.
Price reaction · baseline $32.44 (2026-04-13 close) · hit after-hours · 1 other VCYT headline(s) in the window, move may be shared
day 0 close · peak
+5.7%
day 1
+4.9%
day 3
+4.2%

Market Sentiment Analysis

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.(Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
The conference call will be webcast live from the company’s website and will be available via the following link:https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website athttps://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering via thislink.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visitwww.veracyte.comor follow us onLinkedInorX (Twitter).
Last updated: Apr 14, 2026